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beneﬁtting may decline (i.e. 109 vs. 136 patients in the NORDy-
namIC trial). In addition, practical, pharmacokinetic, and techni-
cal problems may arise: (1) it is essential to take an early
assessment of viral kinetic measurements of HCV RNA viral load
from blood drawn exactly at day 7 and directly before the next
PEG-interferon injection because viral load may ﬂuctuate signiﬁ-
cantly during the initial phase of viral decline. This may be less of
a problem 4 weeks after initiation of antiviral therapy. Indeed, in
our study we found that when retesting a large number of sam-
ples at week 4, undetectable HCV RNA and viral levels below
15 IU/ml had identical predictive values for sustained virologic
response in genotype 1 and 2/3 infected patients [6]. (2) Differ-
ences may be present between the two pegylated interferons alfa
2a and 2b because of different pharmacokinetics (65 vs. a 28 h
elimination half-life, respectively). For pegylated interferon alfa
2b, a more step-wise viral decline is well known. After one week
of therapy a ﬂat or even slightly increasing viral load kinetics may
be seen while a more continuous viral decline is observed with
pegylated interferon alfa 2a. With identical rapid virologic
response rates for both pegylated interferons at week 4 of treat-
ment (IDEAL study 11.4% vs. 11.9% for pegylated interferon alfa
2a vs. 2b, respectively) [7] algorithms with later assessments of
virologic response may be better applicable for these differences.
(3) Finally, despite standardization of IU HCV RNA viral loads
measured with different commercially available assays, these
are not comparable and this is already a problem for the determi-
nation of low vs. high baseline viral load. For a measurement at
day 7 as proposed by Lagging et al., for example 1000 IU/ml by
the Cobas TaqMan assay in genotype 1, 2, 3 infected patients
equals approximately 300, 1000, and 600 IU/ml by realtime
HCV and 300, 600, and 500 IU/ml by the bDNA assay [8–11].
Moreover, a signiﬁcant intra- and inter-assay variability espe-
cially for lower viral loads (0.04–0.13 log10 SD) may make it dif-
ﬁcult to establish a general and precise rule with just one HCV
RNAmeasurement taken early during therapy [10]. Herein, deter-
mination of undetectable HCV RNA levels with a highly sensitive
assay may be superior because all new assays have lower detec-
tion limits between 5 and 10 IU/ml (Cobas TaqMan, realtime HCV,
TMA).
All these parameters have to be taken into account for the cur-
rent standard of care. In the era of direct antiviral agents that dis-
play strong antiviral activities, highly individualized and tailored
treatment durations will be established. The determination of
virologic response with or without additional parameters (base-
line viral load, IL28B polymorphisms etc.) very early during ther-
apy (i.e. between day 3 and week 4) will most likely be required
for the selection of super responders that may beneﬁt from very
short treatments (24 weeks or shorter for genotype 1 and perhaps
even below 12–16 weeks for genotype 2/3 infected patients).
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JOURNAL OF HEPATOLOGYReactivation of autoimmune hepatitis during
budesonide monotherapy, and response to standard treatmentTo the Editor:
The large European trial of budesonide therapy suggests that
budesonide might be better than prednisone in the treatment
of newly diagnosed autoimmune hepatitis [1]. These results were
based on the sensible combination of azathioprine and steroid,Journal of Hepatology 20but already physicians have started using budesonide mono-
therapy, or combinations of budesonide and prednisone or pred-
nisolone. We wish to report a case of autoimmune hepatitis
(AIH), who experienced reactivation of disease activity during
treatment with 3  3 mg budesonide per day and tapering doses11 vol. 54 j 835–839 837
Table 1. Laboratory ﬁndings at presentation and at four time points of treatment.
IgG [g/L] 
ALT [U/L ] 
-GT [U/L] 
Bilirubin [mg/dl] 
AP [U/L]  
SMA-Titer 
At first 
presentation
15.06 
1168 
160 
1.3 
121 
1 : 320 
Treatment
initiation  
79 
24 
0.7 
52 
- 
- 
Increase of 
Prednisolone 
10.98 
217 
33 
0.6 
89 
- 
End of 
Budesonide-treatment
11.11 
47 
27 
0.6 
65 
- 
Azathioprine and Prednisolone 
combination regime 
 + 75 mg Azathioprine
9.04 
20
11 
0.3 
51 
1 : 160  
Prednisolone
15 mg 20 mg 10 mg 5 mg
+ 9 mg Budesonide + 9 mg Budesonide + 9 mg Budesonide 
Letters to the Editorof prednisolone, and at the same time suffered from signiﬁcant
steroid side-effects. Institution of standard therapy with prednis-
olone tapering and azathioprine leads to rapid remission and dis-
appearance of side-effects.
The 22-year-old female patient ﬁrst presented in May 2009
to her general practitioner for a check-up due to non-speciﬁc
mild symptoms, at which time point markedly elevated trans-
aminases (aspartate aminotransferase (AST) 841 U/L, alananine
aminotransferase (ALT) 1357 U/L and gamma-glutamyl-transfer-
ase (c-GT) 155 U/L) were noted (Table 1). Further laboratory
ﬁndings showed a slightly elevated level of total bilirubin
(1.3 mg/dl) and IgG was found to be at the upper limit of nor-
mal (15.06 g/L). Autoantibody testing did only show positivity
for antibodies to smooth muscle antigen (SMA) – titre 1:320 –
(antinuclear antibodies (ANAs), anti-mitochrondrial antibodies
(AMAs), liver-kidney microsomes (LKM), and soluble liver anti-
gen/liver pancreas (SLA/LP) were all negative). Metabolic liver
disease such as Wilson’s Disease and Hemochromatosis were
excluded (coeruloplasmin levels, urine copper, serum iron, and
serum transferrin saturation were within normal range and
eye-examination was inconspicuous). Viral markers for Hepati-
tis A Virus, Hepatitis B Virus, and Hepatitis C Virus were nega-
tive. The patient did not show any history of alcohol abuse nor
did she recently use any known hepatotoxic drugs. Liver biopsy
was not performed at this time point, because the treating phy-
sicians considered the diagnosis of autoimmune hepatitis as suf-
ﬁciently conﬁrmed.
Treatment was started with prednisolone at a starting dose of
60 mg/d (corresponding to 1.3 mg/kg body weight), with a dose
reduction every four days (Fig. 1). Vitamin D and Calcium supple-
mentation were prescribed. Due to steroid speciﬁc side effects,
the patient started feeling agitated and suffered from sleep disor-
der. Prednisolone was gradually reduced to a level of 20 mg/d. As
after an initial fall, transaminases increased again somewhat after
7 weeks of prednisolone induction therapy, and in view of the
steroid side-effects, the patient was put on additional budesonide
at a dose of 3 mg three times daily, while prednisolone was
slowly tapered down to 2.5 mg/d. The patient tolerated budeso-
nide well and transaminases decreased slightly, however, without
reaching normal levels. Steroid-speciﬁc side-effects continued,
but changed their character, as she now gained weight (5 kg in
8 weeks) and developed facial-rounding and hirsutism.838 Journal of Hepatology 2In November 2009, when prednisolone dose had been tapered
to 2.5 mg for 6 weeks, and during continued therapy with
3  3 mg budesonide/d, the patient experienced reactivation of
her AIH with transaminase levels up to 217 U/L ALT. At this stage,
a liver biopsy was performed to conﬁrm reactivation of AIH and
exclude other liver disease including steroid-induced non-
alcoholic staetohepatitis (NASH). Histology showed moderately
severe interface hepatitis (HAI-score 8/18) with dense inﬁltrates
predominantly of plasma cells and lymphocytes. Periportal
lymphocytic piecemeal necrosis with moderate ﬁbrosis without
biliary lesions was identiﬁed. Histology thus demonstrated the
picture of moderately active AIH, despite six months of ade-
quately dosed budesonide. Thepatientwas advisedbyher treating
gastroenterologist to discontinue the intake of desogestrel as oral
contraceptive. Probably, as a consequence of that, considerable
hair loss was triggered as additional unpleasant side-effect. The
treating physicians considered the patient to be treatment refrac-
tory, and prednisolone dose was again raised to 20 mg/d, and then
slowly decreased down to a maintenance dose of 10 mg/d.
At this stage, in February 2010, the patient ﬁrst presented to
our department. At this time point disease was considered only
mildly active with transaminases at the upper limit of normal,
IgG within the normal range, SMA titre of 1:160, and mild symp-
toms of fatigue. Subjective well-being was quite impaired due to
steroid side-effects under the combination therapy with 10 mg
prednisolone daily and 3  3 mg budesonide daily, and in view
of the hair loss. We decided to stop budesonide and start treat-
ment with azathioprine with an initial dose of 50 mg/d (1 mg/
kg) and an increase after two weeks to 75 mg/d. Prednisolone
was then reduced ﬁrst to 7.5 mg/d and after 12 weeks to 5 mg/
d. Azathioprine was well tolerated and the patient responded
quickly to the new combination regimen. Liver enzymes decreased
continuously and normalized for the ﬁrst time. At the same time,
steroid side-effects disappeared. At themoment the patient is feel-
ingwell under azathioprine and low-dose prednisolone treatment.
It is planned to phase out the steroids completely within the next
fewmonths. She is no longer suffering from any treatment-related
side effects. She reintroduced the administration of an oral contra-
ceptive and the hair loss is no longer apparent.
This case demonstrates that in some patients 3  3 mg budes-
onide is insufﬁcient to induce and/or maintain remission in auto-
immune hepatitis, and in this case appeared less effective than011 vol. 54 j 835–839
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Fig. 1. Time course of ALT and IgG during treatment showing reactivation despite therapy with 3  3 mg/day budesonide.
JOURNAL OF HEPATOLOGYprednisolone. In addition, steroid side-effects were considerable,
and these did only change their character when budesonide was
introduced into the treatment. Our group has reported in the
past, that remission can be induced in more than 90% of AIH
within six months by using a starting dose of 1 mg/kg predniso-
lone and introducing azathioprine early at a dose of 1–1.5 mg/kg
body weight [2]. These data were recently conﬁrmed in a second
large patient cohort [3]. These data and the present case should
caution us in the use of budesonide in the treatment of autoim-
mune hepatitis, and further critical evaluation of clinical data will
be needed to deﬁne its exact place in the management of patients
with autoimmune liver disease [4]. Diagnosis should be con-
ﬁrmed by biopsy, and azathioprine should be standard treatment
in all conﬁrmed cases of AIH who can tolerate the drug.
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